Patents Assigned to VAR2 PHARMACEUTICALS APS
  • Targeting of chondroitin sulfate glycans
    Patent number: 11787844
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: October 17, 2023
    Assignee: VAR2 Pharmaceuticals APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • VAR2CSA-drug conjugates
    Patent number: 10675355
    Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: June 9, 2020
    Assignees: VAR2 PHARMACEUTICALS APS, ZYMEWORKS INC.
    Inventors: James R. Rich, John Babcook, Ali El-Salanti, Mads Daugaard, Madeleine Dahlback, Bradley J. Hedberg, Geoffrey C. Winters, Alexander L. Mandel, Elyse Marie Josée Bourque, Tom Han Hsiao Hsieh
  • Compositions and methods for the treatment of platinum-drug resistant cancer
    Patent number: 10517958
    Abstract: VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: December 31, 2019
    Assignees: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APS
    Inventors: John Babcook, James R. Rich, Mads Daugaard, Ali El-Salanti
  • IMMUNOTHERAPEUTIC TARGETING OF PLACENTAL-LIKE CHONDROITIN SULFATE USING CHIMERIC ANTIGEN RECEPTORS (CARS) AND IMMUNOTHERAPEUTIC TARGETING OF CANCER USING CARS WITH SPLIT-PROTEIN BINDING SYSTEMS
    Publication number: 20180298098
    Abstract: The present invention relates to polypeptides comprising conditionally active chimeric antigen receptor (CAR) and a split-protein binding system, a VAR2CSA polypeptide, or any other targeting agent. The present invention further relates to poly-peptides comprising VAR2CSA polypeptides or other targeting agent, and a split-protein binding system.
    Type: Application
    Filed: February 26, 2016
    Publication date: October 18, 2018
    Applicant: VAR2 Pharmaceutical ApS
    Inventor: Mai-Britt Zocca
  • VAR2CSA-DRUG CONJUGATES
    Publication number: 20180117163
    Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 3, 2018
    Applicants: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APS
    Inventors: James R. RICH, John BABCOOK, Ali EL-SALANTI, Mads DAUGAARD, Madeleine DAHLBACK, Bradley J. HEDBERG, Geoffrey C. WINTERS, Alexander L. MANDEL, Elyse Marie Josée BOURQUE, Tom Han Hsiao HSIEH
  • Targeting of chondroitin sulfate glycans
    Patent number: 9932375
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: April 3, 2018
    Assignee: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • Targeting of chondroitin sulfate glycans
    Patent number: 9926350
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 27, 2018
    Assignee: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • VAR2CSA-DRUG CONJUGATES
    Publication number: 20170246310
    Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.
    Type: Application
    Filed: December 29, 2014
    Publication date: August 31, 2017
    Applicants: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APS
    Inventors: James R. RICH, John BABCOOK, Ali EL-SALANTI, Mads DAUGAARD, Madeleine DAHLBACK, Bradley J. HEDBERG, Geoffrey C. WINTERS, Alexander L. MANDEL, Elyse Marie Josée BOURQUE, Tom Han Hsiao HSIEH
  • TARGETING OF CHONDROITIN SULFATE GLYCANS
    Publication number: 20170081373
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: October 5, 2016
    Publication date: March 23, 2017
    Applicant: VAR2 PHARMACEUTICAL APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • TARGETING OF CHONDROITIN SULFATE GLYCANS
    Publication number: 20170016905
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: October 5, 2016
    Publication date: January 19, 2017
    Applicant: VAR2 PHARMACEUTICAL APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
  • TARGETING OF CHONDROITIN SULFATE GLYCANS
    Publication number: 20150004099
    Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).
    Type: Application
    Filed: February 8, 2013
    Publication date: January 1, 2015
    Applicant: VAR2 PHARMACEUTICALS APS
    Inventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen